Open AccessResistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression
Author(s) -
Li Li,
Fuchun Nan,
Qingzhi Guo,
Dongdong Guan,
Chao Zhou
Publication year - 2019
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.204896
Subject(s) - ovarian cancer , bevacizumab , cancer research , medicine , receptor tyrosine kinase , cancer , pharmacology , combination therapy , drug resistance , receptor , chemotherapy , biology , microbiology and biotechnology
Bevacizumab (BV) is broadly used to treat a number of cancers; however, BV resistance mechanisms and strategies to overcome this resistance are yet to be determined.